Thousands of people at higher risk of oesophageal cancer could be offered a quick, less invasive test closer to home under draft guidance from NICE published for consultation today (Monday 16 November 2026).
Our independent committee has recommended Cytosponge and EndoSign to help detect oesophageal cancer and Barrett’s oesophagus in people with persistent gastro-oesophageal reflux disease (GORD), commonly known as acid reflux.
The capsule sponge tests do not require sedation and can be carried out in primary care facilities and community diagnostic centres, rather than in hospital.
The recommendations are the first to be produced through the National HealthTech Access Programme, a new approach designed to identify high-impact medical technologies that, if recommended by NICE, will be funded by the NHS and made consistently available to all eligible patients across the country.
The programme is part of the government’s 10 Year Health Plan and expands our established technology appraisals beyond medicines to selected medical devices, diagnostic tests and digital technologies including those enabled by artificial intelligence (AI).
Barrett’s oesophagus is a condition in which the cells lining the lower part of the food pipe, or oesophagus, change. It affects an estimated 1 to 2% of adults and is more common among people who have long-term acid reflux.
The condition increases the risk of oesophageal cancer, although most people with Barrett’s oesophagus will not develop cancer. Oesophageal cancer can be much harder to treat when it is diagnosed at a later stage, making earlier detection particularly important.
The draft recommendations also give people already diagnosed with Barrett’s oesophagus another option for monitoring their condition. Cytosponge and EndoSign could be used as part of a surveillance programme to periodically check for cellular changes that may indicate oesophageal cancer.
Our committee believes the technologies will help reduce demand on NHS endoscopy services. Demand for endoscopy is high and, in some parts of the NHS, people with Barrett’s oesophagus are not being checked as often as current guidance recommends.
First guidance under the National HealthTech Access Programme
The recommendations are the first to be produced through the National HealthTech Access Programme.
The programme brings together NICE, the Department of Health and Social Care, NHS England, the Medicines and Healthcare products Regulatory Agency and the Office for Life Sciences. It is designed to identify a small number of high-impact medical devices, diagnostic tests and digital technologies and assess whether they should be made routinely available across the NHS.
This means that if a technology is recommended in final NICE guidance, eligible patients across England should be able to access it whenever it is considered the most suitable option for them, rather than availability varying between different parts of the country.
Excerpt from the official page. The original is authoritative. Continue reading at UK NICE ↗